Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: Effect of atorvastatin

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 6, 2007, Pages 1170-1178

  Pignatelli, P ^a   Sanguigni, V ^b   Lenti, L ^a   Loffredo, L ^a   Carnevale, R ^a   Sorge, R ^b   Violi, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

CD40L; Statin; Superoxide anion

Indexed keywords

APOCYNIN; ATORVASTATIN; CD40 LIGAND; CHOLESTEROL; COLLAGEN; FIBRINOGEN RECEPTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G) NITROARGININE METHYL ESTER; OXYGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET THERAPY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; THROMBOCYTE METABOLISM; UPREGULATION;

AUTOANTIBODIES; BLOOD PLATELETS; CASE-CONTROL STUDIES; CD40 LIGAND; ENZYME INHIBITORS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NADPH OXIDASE; OXIDATIVE STRESS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRROLES; SUPEROXIDES; UP-REGULATION;

EID: 34250185760     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02533.x     Document Type: Article

References (32)

1. Schoenbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58: 4-43.
2. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature 1998; 394: 200-3.
3. Freedman JE. CD40-CD40L and platelet function. Beyond haemostasis. Circ Res 2003; 92: 944-6.
4. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
5. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: The switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-9.
6. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-8.
7. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML, CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1163-5.
8. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schonbeck U. Soluble CD40L: Risk prediction after acute coronary syndromes. Circulation 2003; 108: 1049-52.
9. Garlichs CD, John S, Schmeisser A, Eskafi S, Stumpf C, Karl M, Goppelt-Struebe M, Schmieder R, Daniel WG. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001; 104: 2395-400.
10. Sanguigni V, Ferro D, Pignatelli P, Del Ben M, Nadia T, Saliola M, Sorge R, Violi F. CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia. J Am Coll Cardiol 2005; 45: 35-42.
11. Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, Tesauro M, Sorge R, Lauro R, Violi F. Short-Term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005; 111: 412-9.
12. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
13. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P, Violi F. gp91phox-dependent expression of platelet CD40 ligand. Circulation 2004; 110: 1326-9.
14. Reilly MP, Pratico D, Delanty N, DiMinno G, Tremoli E, Rader D, Kapoor S, Rokach J, Lawson J, FitzGerald GA. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 1998; 98: 2822-8.
15. De Caterina R, Cipollone F, Filardo FP, Zimarino M, Bernini W, Lazzerini G, Bucciarelli T, Falco A, Marchesani P, Muraro R, Mezzetti A, Ciabattoni G. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: No further effect of vitamin E. Circulation 2002; 106: 2543-9.
16. Sanguigni V, Pignatelli P, Caccese D, Pulcinelli FM, Lenti L, Magnaterra R, Martini F, Lauro R, Violi F. Increased superoxide anion production by platelets in hypercholesterolemic patients. Thromb Haemost 2002; 87: 796-801.
17. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-5.
18. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 1998; 91: 484-90.
19. Pignatelli P, Lenti L, Sanguigni V, Frati G, Simeoni I, Gazzaniga PP, Pulcinelli FM, Violi F. Carnitine inhibits arachidonic acid accumulation into platelet phospholipids. Effects on platelet function and oxidative stress. Am J Physiol Heart Circ Physiol 2003; 284: H41-8.
20. Jaimes EA, DeMaster EG, Tian RX, Raij L. Stable compounds of cigarette smoke induce endothelial superoxide anion production via NADPH oxidase activation. Arterioscler Thromb Vasc Biol 2004; 24: 1031-6.
21. VandenBroeke T, Dumont LJ, Hunter S, Nixon J, Murphy S, Roger J, Herschel L, AuBuchon JP, Gulliksson H, Dengler T, Hornsey V, Prowse C. Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. Platelet storage solution affects on the accuracy of laboratory tests for platelet function: A multi-laboratory study. Vox Sang 2004; 86: 183-8.
22. Pignatelli P, Di Santo S, Buchetti B, Sanguigni V, Brunelli A, Violi F. Polyphenols enhance platelet nitric oxide by inhibiting protein kinaseC-dependent NADPH oxidase activation: Effect on platelet recruitment. FASEB J 2006; 20: 1082-9.
23. Seno T, Inoue N, Gao D, Okuda M, Sumi Y, Matsui K, Yamada S, Hirata KI, Kawashima S, Tawa R, Imajoh-Ohmi S, Sakurai H, Yokoyama M. Involvement of nadh/nadph oxidase in human platelet ROS production. Thromb Res 2001; 103: 399-409.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951; 193: 265-71.
25. Davis C. Statistical Methods for the Analysis of Repeated Measurements. New York: Springer, 2002.
26. Keaney JF Jr. Oxidative stress and the vascular wall: NADPH oxidases take center stage. Circulation 2005; 112: 2585-8.
27. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997; 100: 350-6.
28. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271: C1424-37.
29. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002; 8: 247-52.
30. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol 2005; 25: 2428-34.
31. Stern RH, Yang BB, Hounslow NJ, MacMahon M, Abel RB, Olson SC. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 2000; 40: 616-23.
32. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, Falco A, Cuccurullo F, Davi G. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: Effects of statin therapy. Circulation 2002; 106: 399-402.